Recent Publications 2010-2012

Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial.

Left atrial appendage occlusion for the reduction of stroke and embolism in patients with atrial fibrillation.
Gibson DN, Price MJ, Ahern TS, Teirstein PS.

Platelet-mediated thrombosis and drug-eluting stents.

The brave new world of antiplatelet therapy: seeking clarity in a world of increasing choice and complexity.
Price MJ.

Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data.

Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, Berger PB, Tanguay JF, Cannon CP, Topol EJ.

The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors.
Price MJ, Tantry US, Gurbel PA.

Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.

Clinical outcomes following predilation with a novel 1.25-mm diameter angioplasty catheter.
Recent Publications 2010–2012

Functional testing methods for the antiplatelet effect of P2Y12 receptor antagonists.
Price MJ, Barker CM.

Intraprocedural stent thrombosis during crush stenting of the left main coronary artery bifurcation.
Nayak KR, Mehta HS, Barker CM, Price MJ.

Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity.
Barker CM, Murray SS, Teirstein PS, Kandzari DE, Topol EJ, Price MJ.

Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.
Working Group on High On-Treatment Platelet Reactivity.

Longer-term outcomes of paclitaxel stent implantation as an initial treatment strategy for sirolimus-eluting stent restenosis.

The evidence base for platelet function testing in patients undergoing percutaneous coronary intervention.
Price MJ.

A novel technique for ultra-low contrast administration during angiography or intervention.

Identifying the “optimal” duration of dual antiplatelet therapy after drug-eluting stent revascularization.
Kandzari DE, Angiolillo DJ, Price MJ, Teirstein PS.

Utility of on-line three-dimensional transesophageal echocardiography during percutaneous atrial septal defect closure.
Price MJ, Smith MR, Rubenson DS.

The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study.
Recent Publications 2010–2012

Characterization of circulating endothelial cells in acute myocardial infarction.

Whole Blood Gene Expression Testing for Coronary Artery Disease in Nondiabetic Patients: Major Adverse Cardiovascular Events and Interventions in the PREDICT Trial.

Is there a clinically significant interaction between calcium channel antagonists and clopidogrel?: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
Good CW, Steinhubl SR, Brennan DM, Lincoff AM, Topol EJ, Berger PB.

Dual or Mono Antiplatelet Therapy for Patients With Acute Ischemic Stroke or Transient Ischemic Attack: Systematic Review and Meta-Analysis of Randomized Controlled Trials.

The unmet need of education in genomic medicine.
Patay BA, Topol EJ.

Comparative gene expression analysis between coronary arteries and internal mammary arteries identifies a role for the TES gene in endothelial cell functions relevant to coronary artery disease.

Association of direct-to-consumer genome-wide disease risk estimates and self-reported disease.
Bloss CS, Topol EJ, Schork NJ.

Comparison of incidence of bleeding and mortality of men versus women with ST-elevation myocardial infarction treated with fibrinolysis.

Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Is pocket mobile echocardiography the next-generation stethoscope? A cross-sectional comparison of rapidly acquired images with standard transthoracic echocardiography.
Liebo MJ, Israel RL, Lillie EO, Smith MR, Rubenson DS, Topol EJ.

Longitudinal stent deformation: quantitative coronary angiographic analysis from the PERSEUS and PLATINUM randomised controlled clinical trials.
Kereiakes DJ, Popma JJ, Cannon LA, Kandzari DE, Kimmelstiel CD, Meredith IT, Teirstein PS, Verheyse S, Allocco DJ, Dawkins KD, Stone GW.

Two-Year Outcomes after Transcatheter or Surgical Aortic-Valve Replacement.

Five-year follow-up of the Sirolimus-Eluting Stents vs Vascular Brachytherapy for Bare Metal In-Stent Restenosis (SISR) trial.

Percutaneous coronary intervention use in the United States: defining measures of appropriateness.
Marso SP, Teirstein PS, Kereiakes DJ, Moses J, Lasala J, Grantham JA.

PLATINUM QCA: a prospective, multicentre study assessing clinical, angiographic, and intravascular ultrasound outcomes with the novel platinum chromium thin-strut PROMUS Element everolimus-eluting stent in de novo coronary stenoses.

Engineered virus-like nanoparticles reverse heparin anticoagulation more consistently than protamine in plasma from heparin-treated patients.
Gale AJ, Elias DJ, Averell PM, Teirstein PS, Buck M, Brown SD, Polonskaya Z, Udit AK, Finn MG.

A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial.
Stone GW, Teirstein PS, Meredith IT, Farah B, Dubois CL, Feldman RL, Dens J, Hagiwara N, Allocco DJ, Dawkins KD; PLATINUM Trial Investigators.

Clinical outcomes following predilation with a novel 1.25-mm diameter angioplasty catheter.
Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity.
Barker CM, Murray SS, Teirstein PS, Kandzari DE, Topol EJ, Price MJ.

Teirstein PS.

Comparison of long-term (4-year) outcomes of patients with unprotected left main coronary artery narrowing treated with drug-eluting stents versus coronary-artery bypass grafting.
Am J Cardiol. 2010 Jun 15;105(12):1728-34.

Longer-term outcomes of paclitaxel stent implantation as an initial treatment strategy for sirolimus-eluting stent restenosis.

A novel technique for ultra-low contrast administration during angiography or intervention.

Identifying the “optimal” duration of dual antiplatelet therapy after drug-eluting stent revascularization.
Kandzari DE, Angiolillo DJ, Price MJ, Teirstein PS.

Dual catheter technique for the treatment of severe coronary artery perforations.

A randomized controlled trial of angiography versus intravascular ultrasound-directed bare-metal coronary stent placement (the AVID Trial).

Change we can believe in: the hyper-evolution of percutaneous coronary intervention for unprotected left main disease with drug-eluting stents.
Price MJ, Kandzari DE, Teirstein PS.

Three-year outcome of drug-eluting stent implantation for coronary artery bifurcation lesions.
Stinis CT, Hu SP, Price MJ, Teirstein PS.
Recent Publications 2010–2012

B-type natriuretic peptide assessment in ambulatory heart failure patients: insights from IMPROVE HF.
Ambrosy AP, Fonarow GC, Albert NM, Curtis AB, Heywood JT, Mehra MR, O’Connor CM, Reynolds D, Walsh MN, Yancy CW, Gheorghiade M.

Lack of association between electronic health record systems and improvement in use of evidence-based heart failure therapies in outpatient cardiology practices.
Walsh MN, Albert NM, Curtis AB, Gheorghiade M, Heywood JT, Liu Y, Mehra MR, O’Connor CM, Reynolds D, Yancy CW, Fonarow GC.

Factors associated with improvement in ejection fraction in clinical practice among patients with heart failure: findings from IMPROVE HF.
Wilcox JE, Fonarow GC, Yancy CW, Albert NM, Curtis AB, Heywood JT, Inge PJ, McBride ML, Mehra MR, O’Connor CM, Reynolds D, Walsh MN, Gheorghiade M.

Factors associated with improvement in guideline-based use of ICDs in eligible heart failure patients.
Mehra MR, Albert NM, Curtis AB, Gheorghiade M, Heywood JT, Liu Y, O’Connor CM, Reynolds D, Walsh MN, Yancy CW, Fonarow GC.

Continuous hemodynamic monitoring in patients with mild to moderate heart failure: results of The Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (REDUCEhf) trial.

Modulation of novel cardiorenal and inflammatory biomarkers by intravenous nitroglycerin and nesiritide in acute decompensated heart failure: an exploratory study.

Associations between outpatient heart failure process-of-care measures and mortality.
Fonarow GC, Albert NM, Curtis AB, Gheorghiade M, Heywood JT, Liu Y, Mehra MR, O’Connor CM, Reynolds D, Walsh MN, Yancy CW.

Renal function and neurohormonal changes following intravenous infusions of nitroglycerin versus nesiritide in patients with acute decompensated heart failure.

Stiff left atrial syndrome after catheter ablation for atrial fibrillation: clinical characterization, prevalence, and predictors.
Recent Publications 2010–2012

Patient and practice factors associated with improvement in use of guideline-recommended therapies for outpatients with heart failure (from the IMPROVE HF trial).
O’Connor CM, Albert NM, Curtis AB, Gheorghiade M, Heywood JT, McBride ML, Inge PJ, Mehra MR, Reynolds D, Walsh MN, Yancy CW, Fonarow GC.

Equitable improvement for women and men in the use of guideline-recommended therapies for heart failure: findings from IMPROVE HF.
Walsh MN, Yancy CW, Albert NM, Curtis AB, Gheorghiade M, Heywood JT, Inge PJ, McBride ML, Mehra MR, O’Connor CM, Reynolds D, Fonarow GC.

Direct left atrial pressure monitoring in severe heart failure: long-term sensor performance.

Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF).
Fonarow GC, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, McBride ML, Mehra MR, O’Connor CM, Reynolds D, Walsh MN, Yancy CW.

Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF.
Heywood JT, Fonarow GC, Yancy CW, Albert NM, Curtis AB, Gheorghiade M, Inge PJ, McBride ML, Mehra MR, O’Connor CM, Reynolds D, Walsh MN.
Circ Heart Fail. 2010 Sep;3(5):596-605.

Outpatient cardiology practices with advanced practice nurses and physician assistants provide similar delivery of recommended therapies (findings from IMPROVE HF).
Albert NM, Fonarow GC, Yancy CW, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, McBride M, Mehra MR, O’Connor CM, Reynolds D, Walsh MN.

Influence of renal function on the use of guideline-recommended therapies for patients with heart failure.
Heywood JT, Fonarow GC, Yancy CW, Albert NM, Curtis AB, Stough WG, Gheorghiade M, McBride ML, Mehra MR, O’Connor CM, Reynolds D, Walsh MN.

Electronic health records and quality of care for heart failure.
Walsh MN, Yancy CW, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, McBride ML, Mehra MR, O’Connor CM, Reynolds D, Fonarow GC.

Physician-directed patient self-management of left atrial pressure in advanced chronic heart failure.
Circulation. 2010 Mar 9;121(9):1086-95.
Influence of dedicated heart failure clinics on delivery of recommended therapies in outpatient cardiology practices: findings from the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF).
Albert NM, Fonarow GC, Yancy CW, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, McBride M, Mehra MR, O’Connor CM, Reynolds D, Walsh MN.
Am Heart J. 2010 Feb;159(2):238-44.

Adherence to guideline-recommended adjunctive heart failure therapies among outpatient cardiology practices (findings from IMPROVE HF).
Yancy CW, Fonarow GC, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, McBride ML, Mehra MR, O’Connor CM, Reynolds D, Walsh MN.

Is computed tomographic angiography prognostic in patients with cardiac symptoms?
Suhar CJ, Hitchcock TM, Russo RJ, Topol EJ.
J Am Coll Cardiol. 2008 Apr 15;51(15):1510; author reply 1510-1. No abstract available.

Salvage of pacemakers and automatic implantable cardioverter-defibrillators using dermis grafts.
Rudolph R, Smith MR, Curtis GP.

Pulmonary Vein Isolation for the Treatment of Drug-Refractory Atrial Fibrillation in Adults with Congenital Heart Disease.
Philip F, Muhammad KI, Agarwal S, Natale A, Krasuski RA.
Congenit Heart Dis. 2012 Apr 2.

Fragmented And Delayed Electrograms Within Fibro-Fatty Scar Predict Arrhythmic Events In Arrhythmogenic Right Ventricular Cardiomyopathy: Results from a Prospective Risk Stratification Study.

Impact of metabolic syndrome on procedural outcomes in patients with atrial fibrillation undergoing catheter ablation.
J Am Coll Cardiol. 2012 Apr 3;59(14):1295-301.

Circ Arrhythm Electrophysiol. 2012 Mar 15.

Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry.
Recent Publications 2010–2012


The durability of pulmonary vein isolation using the visually guided laser balloon catheter: Multicenter results of pulmonary vein remapping studies.

Ablation of Atrial Fibrillation under Therapeutic Warfarin Reduces Periprocedural Complications: Evidence from a Meta-Analysis.
Circ Arrhythm Electrophysiol. 2012 Jan 23.

Catheter ablation of atrial fibrillation: state-of-the-art techniques and future perspectives.

Delayed cardiac tamponade after radiofrequency catheter ablation of atrial fibrillation: a worldwide report.

Am J Cardiol. 2009 Apr 1;103(7):917-22.

Am J Cardiol. 2008 Nov 1;102(9):1151-5.